The share prices of Zogenix, Inc. (NASDAQ:ZGNX) had increased by 8.48 percent to close at $1.79 per share for the last trading session on Tuesday. The shares of the company had been trading in the range of $1.58 to $1.80 per during the day. The shares Zogenix, Inc. (NASDAQ:ZGNX) had a total market capitalization of $180.45 million. The stock opened at $1.66 per share. The share price does not make a change in the 52 week low value $1.11 per share and 52 week high value $3.30 per share.
The company focused on developing and commercializing various products for curing the central nervous system disorders and pain. This company is a pharmaceutical based company. Many physicians and Patients in the United States use Sumavel DosePro and Zohydro for their treatment. Sumavel DosePro delivers needle-free subcutaneous administration of sumatriptan for curing the cluster headache and migraine is the company’s product. In 2011, the company finished Zohydro is the development of Phase 3. An injectable formulation of risperidone for the treatment of schizophrenia is Relday and this is the second DosePro investigational product candidate. A NDA to the Food and Drug Administration was submitted by the company on May 2012.
SUMAVEL DosePro Migraine Toolbox was launched by the company to support patient education and empowerment. The specialty of this toolbox is that the patient’s having appropriate medication on hand. The majority of sufferers (54 percent) told that their prescription oral migraine medication is not useful for every migraine attack this was founded by a National Headache Foundation survey of 500 migraine sufferers. The company had an institutional investor’s shareholdings as 78 percent. Zogenix, Inc. (NASDAQ:ZGNX) has been having an average volume as 505,562 per day on Tuesday. The company presently holds 100.81 million shares outstanding in the market.